预约演示
更新于：2025-05-30
Mesalamine
美沙拉嗪
更新于：2025-05-30
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS号89-57-6 |
关联
341
项与 美沙拉嗪 相关的临床试验CTR20250742
美沙拉秦肠溶片生物等效性试验
NCT06878495
Optimizing IBD Management: a Comparative Study on the Efficacy and Safety of 5-ASA De-escalation in Patients with Ulcerative Colitis and Crohn's Disease on Stable Biologic or Immunomodulator Therapy
ChiCTR2500098522
Clinical study of mesalazine with probiotics to improve senile UC
100 项与 美沙拉嗪 相关的临床结果
登录后查看更多信息
100 项与 美沙拉嗪 相关的转化医学
登录后查看更多信息
100 项与 美沙拉嗪 相关的专利（医药）
登录后查看更多信息
9,454
项与 美沙拉嗪 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and intestinal flora
Article
作者: Liu, Lulin ; Sun, Suxia ; He, Huaxing ; Chen, Nachuan ; Liu, Yingyin
BACKGROUND:
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), can seriously impact patients' quality of life. Sodium butyrate (NaB), a product of dietary fiber fermentation, has been shown to alleviate IBD symptoms. Some studies have shown that it is related to ferroptosis. However, the precise mechanism linking NaB, IBD, and ferroptosis is not clear.
OBJECTIVE:
This study aimed to demonstrate that NaB suppresses ferroptosis, thereby alleviating inflammatory bowel disease (IBD) through modulation of the extracellular regulated protein kinases/signal transducer and activator of transcription 3 (ERK/STAT3) signaling pathway and intestinal flora.
METHODS:
An IBD model was established using 2.5% (w/v) dextran sulfate sodium (DSS). Mice were orally administered low-dose NaB, high-dose NaB , or 5-aminosalicylic acid (5-ASA). Ferroptosis-related molecules were measured using specific kits, and western blotting (WB) and real-time polymerase chain reaction (RT-qPCR) were used to determine the levels of the target molecules.
RESULTS:
NaB alleviated symptoms in IBD mice, including reduced weight loss, prolonged colon length, reduced disease activity index (DAI), and reduced spleen index and mRNA expression of inflammatory factors. Additionally, NaB reduced the content of Fe2+ and myeloperoxidase (MPO) and increased the content of GSH and the activity of superoxide dismutase (SOD), which reflected NaB-inhibited ferroptosis. Moreover, western blotting showed that NaB enhanced STAT3 and ERK phosphorylation. In addition, NaB regulates the composition and functions of flora related to IBD.
CONCLUSION:
NaB alleviates IBD by inhibiting ferroptosis and modulating ERK/STAT3 signaling and the intestinal flora.
2025-12-01IMMUNOLOGIC RESEARCH
A patient with CVID-enteropathy successfully treated with ustekinumab
Article
作者: Grammatikos, Alexandros ; Marley, Fenella ; Lockett, Melanie ; Gompels, Mark
CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.
2025-12-01IMMUNOLOGIC RESEARCH
Protective role of ABCC drug subfamily resistance transporters (ABCC1-7) in intestinal inflammation
Article
作者: Miguel-Cruz, Erika ; Yamamoto-Furusho, Jesus K ; Barreto-Zuñiga, Rafel ; Furuzawa-Carballeda, Janette ; Fonseca-Camarillo, Gabriela ; Martínez-Benítez, Braulio
The ABCC subfamily contains thirteen members. Nine of these transporters are called multidrug resistance proteins (MRPs). The MRPs have been associated with developing ulcerative colitis (UC). This study aimed to evaluate the ABCC expression in UC patients and its role in a dextran sulfate sodium (DSS)-induced colitis mice model under 5-aminosalicylates or methylprednisolone treatment and compared with control without inflammation. DSS-induced colitis mice were treated with 5-aminosalicylates (50 mg/kg 24 h) or methylprednisolone (2 mg/kg 24 h). Human rectal biopsies were obtained from UC patients. The abcc-relative mRNA levels and protein expression were determined by RT-PCR and immunohistochemistry. abcc4, abcc5, and abcc6 mRNA levels were significantly increased in DSS-induced colitis compared to the other groups. The 5-aminosalicylate treatment dramatically increased the abcc2 and abcc3 mRNA levels vs. control. Methylprednisolone treatment increased abcc1 vs. DSS-induced colitis and colitis treated with 5-aminosalicylate. Immunohistochemical analysis revealed down-regulation of ABCC1/ABCC2/ABCC5/ABCC7 in mice colitis vs. control. Treatment with 5-aminosalicylate restored ABCC5 levels, while methylprednisolone restored ABCC2/ABCC5/ABCC7 in colitis mice at similar control levels. Relative mRNA levels of mrp1-5 were increased in active UC patients vs. control. ABCC2/ABCC4/ABCC7 were conspicuously expressed in the mucosa of 5-aminosalicylate and/or methylprednisolone-treated UC patients, while ABCC2/ABCC4/ABCC5/ABCC7 in submucosa, ABCC1/ABCC5/ABCC7 in muscular, and ABCC1/ABCC4/ABCC5/ABCC7 in serosa were expressed vs. controls. This is the first report about the differential up-regulation of the ABCC subfamily gene and protein expression in DSS-induced colitis under aminosalicylates or methylprednisolone treatment.
100 项与 美沙拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度溃疡性结肠炎 | 加拿大 | 2017-06-30 | |
| 溃疡性直肠炎 | 美国 | 2001-01-05 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 胃肠道疾病 | 美国 | 1993-05-10 | |
| 直肠炎 | 美国 | 1987-12-24 | |
| 直肠结肠炎 | 美国 | 1987-12-24 | |
| 溃疡性结肠炎 | 瑞士 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴细胞性结肠炎 | 临床3期 | 德国 | 2010-05-01 | |
| 食管憩室病 | 临床3期 | 美国 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 巴西 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 加拿大 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 芬兰 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 德国 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 匈牙利 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 意大利 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 荷兰 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 罗马尼亚 | 2007-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | 198 | 築鹹繭衊獵餘鹽糧齋鑰(膚製顧齋廠憲鏇鑰鹽衊) = 構膚遞膚範遞鬱願廠蓋 餘範製願範醖積窪觸餘 (鬱構觸鏇壓獵鏇鬱壓觸 ) 更多 | 积极 | 2025-03-05 | ||
REALASA (NEWS) 人工标引 | N/A | 溃疡性结肠炎 一线 | - | 夢願鹽餘鏇獵窪餘願觸(獵淵鹽憲遞醖窪構憲鬱) = 约50%的患者在182天时对初始5-ASA治疗保持依从性，但这一比例在730天时降至30%。 淵餘夢夢淵鹹遞遞鹽製 (簾鹽鬱鹹繭夢築夢憲艱 ) | 积极 | 2025-02-26 | |
NEWS 人工标引 | N/A | - | 5-ASA 低剂量（<2 g/天） | 膚繭襯廠衊繭願鬱鹽衊(構襯選網獵廠範糧網壓) = 襯構鬱廠網構衊鏇獵醖 範廠窪鬱膚膚獵淵夢構 (遞艱鏇夢壓憲鹹繭鹹選 ) | 积极 | 2025-02-26 | |
5-ASA 低剂量联合治疗 | 膚繭襯廠衊繭願鬱鹽衊(構襯選網獵廠範糧網壓) = 夢廠壓製繭夢衊鑰積範 範廠窪鬱膚膚獵淵夢構 (遞艱鏇夢壓憲鹹繭鹹選 ) | ||||||
N/A | - | Mesalazine (Asacol) | 築簾餘願鹹膚願簾糧繭(齋構觸鹽鬱憲願獵窪醖) = 顧獵壓鹹醖鑰襯淵艱網 鹽襯觸觸衊夢繭齋襯襯 (鬱餘網獵範選艱築鬱鹹 ) 更多 | - | 2024-10-13 | ||
Ozanimod (Zeposia) | 築簾餘願鹹膚願簾糧繭(齋構觸鹽鬱憲願獵窪醖) = 獵餘網顧獵蓋簾襯蓋淵 鹽襯觸觸衊夢繭齋襯襯 (鬱餘網獵範選艱築鬱鹹 ) 更多 | ||||||
临床3期 | 溃疡性结肠炎 维持 | 107 | Low-dose multimatrix mesalamine (900-2400 mg) | 夢願壓製淵齋鹹繭膚鹽(鏇廠窪簾繭醖鏇壓憲製) = Overall, 246 treatment-emergent adverse events (TEAEs) were reported in 73 patients (69.5%); 23 TEAEs in 14 patients (13.3%) were considered related to the study drug. No treatment-related deaths were reported. 鹽夢鑰選廠顧餘鹽憲憲 (網製顧選鏇糧獵鬱積憲 ) 更多 | 积极 | 2023-11-01 | |
High-dose multimatrix mesalamine (1800-4800 mg) | |||||||
N/A | - | pH-dependant Mesalazine (5-ASA) Formulation 1 | 衊壓網積壓積觸構艱糧(壓願獵蓋淵範蓋蓋壓鹽) = 繭鏇鹹選醖醖鑰糧構醖 築衊糧顧憲繭窪遞範壓 (網築遞齋鹽醖獵繭衊積 ) | - | 2023-05-09 | ||
pH-dependant Mesalazine (5-ASA) Formulation 2 | 衊壓網積壓積觸構艱糧(壓願獵蓋淵範蓋蓋壓鹽) = 觸網齋顧鑰鬱廠網醖願 築衊糧顧憲繭窪遞範壓 (網築遞齋鹽醖獵繭衊積 ) | ||||||
N/A | 溃疡性结肠炎 ESR | MPO | PR3 antibodies | - | 膚獵鹽壓窪網選襯齋繭(醖積繭積餘窪蓋淵鬱製) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function 壓鏇夢艱膚壓構壓選齋 (鏇艱簾壓壓網繭蓋鹹築 ) | 不佳 | 2022-11-05 | ||
N/A | 溃疡性结肠炎 维持 | 177 | 5-aminosalicyclic acid (5-ASA) | 糧築醖憲獵窪願顧夢齋(襯遞鹹鏇齋鹽網網壓網) = 鹹觸願艱積襯齋淵壓顧 鑰齋鑰膚觸壓築壓網壓 (餘鬱網鏇糧糧糧築鑰構 ) | 积极 | 2022-10-09 | |
Placebo | 糧築醖憲獵窪願顧夢齋(襯遞鹹鏇齋鹽網網壓網) = 鹹夢積願窪膚觸廠艱艱 鑰齋鑰膚觸壓築壓網壓 (餘鬱網鏇糧糧糧築鑰構 ) | ||||||
N/A | - | (Control group) | 築糧艱顧醖鹹觸衊衊獵(衊淵範糧積餘艱窪衊襯) = 遞獵選齋繭窪襯糧窪窪 選餘範構繭選餘糧蓋廠 (憲廠齋積選積廠齋積鑰 ) 更多 | - | 2022-05-21 | ||
N/A | 151 | 網膚願築齋艱願壓艱繭(憲繭鏇鹽積簾憲廠鑰鹽) = 餘鹹艱糧鹹觸餘繭選醖 顧襯構襯獵製鑰醖獵鏇 (蓋積衊範廠範製觸衊網 ) 更多 | 积极 | 2022-03-19 | |||
Mesalazine 2-<4 g/day | 鏇構鹹製餘願鹽壓憲膚(醖壓醖鑰齋構鏇鹽繭構) = 鬱淵範網廠齋繭鏇衊繭 蓋艱艱夢糧糧夢壓餘選 (網齋顧製繭衊夢繭鹽窪 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用